POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 4 / 2018
Prepared on: 2018-01-11

Abbreviated name of the issuer
MABION S.A.

Subject matter
Information on the last visit of the last patient in the MabionCD20 NHL trial and the conclusion of long-term observation.

Legal basis
Article 17(1) of the Market Abuse Regulation – inside information

Content of the report:
With regard to Current Report no. 40/2017 of 28 August 2017 on the end of medicine administration in the MabionCD20 NHL trial, the Management Board of Mabion S.A. ("Company") informs that on 11 January 2018 it became aware on the last visit of the last patient which took place as part of the additional observation period (so-called long-term observation of patients recruited in the MabionCD20 NHL trial. Summing up, all patients taking part in the MabionCD20 NHL trial ended the 46-week treatment and observation cycle comprising the basic treatment and observation period lasting 26 weeks and additional 20 weeks of long-term observation. Thus, the gathering of data for all endpoints in the trial was completed. On the basis of the data collected, the Company shall obtain results in the scope of secondary endpoints connected with long-term observation. The Company does not plan to separately provide information on this results due to their limited significance when compared to results presented in Current Reports no. 2/2018 of 5 January 2018 (results in the scope of primary pharmacokinetic endpoints) and no. 3/2018 of 10 January 2018 (results in the scope of certain secondary endpoints). For the above reasons, the Company shall publish, in the scope of results of the MabionCD20 NHL trial, only a current report concerning the second part of secondary endpoints related to pharmacokinetics and pharmacodynamics.